secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001493152-24-004066
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio reports positive preclinical data for PALI-2108 UC therapy; Phase 1 planned for 2024
--------------------------------------------------------------------------------

- PALI-2108 showed colon-selective bioactivation with colon/plasma AUC ratio >200.
- In DSS-induced UC mouse model, significant reduction in disease activity index over time.
- No CNS toxicity or emesis observed in dogs at effective doses.
- Company advancing PALI-2108 toward Phase 1 clinical study, expected to start in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315224004066/0001493152-24-004066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315224004066/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-004066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer